Back

Microbial Strain Development Strategy to Enhance Product Development

An efficient microbial strain development strategy stands as the cornerstone of expediting product development timelines and enhancing the overall product development process. Leveraging an in-house generated toolbox not only streamlines strain construction but also enables simultaneous screening, significantly reducing the number of developmental cycles required. Despite the importance of having a standardized workflow, having adaptability also caters to the distinct needs of specific products and processes. Moreover, all strains should be meticulously crafted to seamlessly integrate into a robust fermentation process optimal for product expression with required quality attributes. This type of strain development design ensures efficient scale-up into both Single-Use (SUF) and Stainless Steel (SS) fermenters, highlighting the versatility and effectiveness of such development strategy.

In the beginning of the strain development approach, the choice between genetic engineering and evolutionary optimization methods, such as classical breeding in yeast or induced mutations in E. coli, should be tailored to the specific needs of customers and the demands of their respective product and market environments. Whether it’s the precision of genetic engineering or the natural selection of evolutionary optimization, the goal is always to achieve maximum strain productivity. There is a diverse array of cutting-edge technologies that can be employed, including microbial gene transfer and expression toolboxes, Next-Generation Sequencing (NGS), applied bioinformatics, and the identification of novel enzyme genes or gene clusters containing pathways of interest. This comprehensive list of technologies can be even further augmented by pathway and enzyme engineering techniques, all seamlessly integrated with bioanalytics and bioprocess development. Taking a holistic approach like this ensures the synchronized advancement of both strain and process, guaranteeing a coherent and optimized development path. 

As scale-up is always an important consideration, the integration of systems and synthetic biology tools offers a promising avenue for the design and optimization of microbial strains, specifically facilitating reliable and robust production at large scales. Systems biology techniques can play a crucial role in evaluating microbial systems’ responses to various stressors within fermenters, such as nutrient fluctuations and dissolved gases. Meanwhile, synthetic biology enables both the assessment and modulation of strain responses, allowing the engineering of strains to enhance production efficiency. Throughout the scale-up process, spanning from microtiter plates to bench-scale fermenters and commercial fermenters, there are multiple chemical, physical, and biological factors that can impede microbial growth and product formation. Addressing these challenges therefore requires a tailored and strategic approach, as the specific hurdles encountered during scale-up vary depending on the host and the final cultivated product. 

One critical decision to make during a microbial strain development process is on the host: should you take a bacterial (i.e. E. coli) or a yeast approach? It’s crucial to consider the advantages and limitations of each. E. coli offers rapid growth rates and well-characterized genetic tools, making it ideal for high-throughput screening and genetic manipulation. However, its endotoxin production, inability to secrete proteins into the growth medium, and limited post-translational modification capabilities can pose challenges for certain applications. On the other hand, yeast, particularly Saccharomyces cerevisiae, is often favored for its scalability and ability to perform complex metabolic pathways. However, its slower growth rate compared to E. coli and higher media costs may deter its use in some cases. The suitability of each approach for different product types and applications depends on factors such as the desired protein characteristics, scale of production, and downstream processing requirements. Here at Cytovance, we have strategic partnerships with both E. coli and yeast experts to enable optimized, state-of-the-art strain development for both kinds of host systems.

The Power of Partnership:

Our partnership with the E. coli experts at Vectron Biosolutions allows us to leverage their proprietary expression and secretion technologies and vast expertise to custom-engineer vectors that can be utilized in a variety of bacterial strains tailored to the unique requirements of each customer’s protein. Through meticulous genetic manipulation and optimization, the vectors are designed to yield maximal titers of biologically active proteins, ensuring enhanced performance in downstream applications. The workflow begins with a feasibility study to assess the viability of the project, followed by successive work aimed at fine-tuning the genetics of the vector to obtain a tailored expression vector designed for optimal production of each specific protein. This results in very high titers at low cost, exceeding 40 g/L for many proteins. Depending upon the protein of interest, the expression vectors may then be used in secretory E. coli strains to achieve secreted titers in the g/L scale. This greatly reduces downstream processing costs, but also prevents inclusion body formation, protein-specific host cell toxicity, and proteolytic degradation of the protein. While much of the screening is conducted at the microtiter scale for efficiency, all strains undergo rigorous testing under high cell-density fed-batch conditions to simulate real-world production environments and ensure scalability. This iterative approach allows us to deliver highly efficient and reliable solutions to our clients, meeting their diverse protein expression needs with precision and efficacy.

When working with yeast strain development, Phenotypeca’s QTL technology stands at the forefront of strain optimization, seamlessly integrating its proprietary breeding method with genomic-based screening to fine-tune strains for specific proteins and their demands. By targeting quantitative trait loci (QTL) within the genome, which drive crucial aspects of protein production, this approach ensures unparalleled precision. Leveraging a diverse library of baker’s yeast strains, Phenotypeca selects parent strains guided by proprietary genomic insights and project requirements. Through initial breeding, billions of progeny strains are generated and meticulously screened to identify top performers, with QTL analysis guiding the selection of parent strains for subsequent rounds. This iterative process, involving continuous breeding, screening, and QTL analysis, leads to performance improvements with each cycle until all project objectives are met or biological capabilities reaches its limits. Unlike conventional methods, such as rational strain engineering or mutagenesis, QTL technology excels in multi-parameter optimization, offering tailor-made solutions for premium recombinant protein manufacturing processes, perfectly aligned with our client’s needs. Check out one of Phenotypeca’s case studies to learn more about how we are shaping the future of antibody therapeutics.

The strategies outlined here represent an exciting shift in microbial product development, emphasizing precision, efficiency, and market alignment. From leveraging proprietary expression technologies to cutting-edge techniques for strain optimization, each approach is meticulously designed to meet the specific demands of protein production. Utilizing these strategies, we have the ability to streamline development timelines, reduce costs, and ensure the reliable production of high-quality proteins. Furthermore, the integration of these approaches into commercial settings promises to enable the scalable manufacture of complex proteins tailored to diverse product needs. 

A three-minute investment could make all the difference for your molecule! Hear from our experts themselves on why we are the right choice to guide your program to its next milestone here.